AstraZeneca drug reduces flare-ups of chronic lung disease in late-stage trials

By Pushkala Aripaka, Nithyashree R B and Maggie Fick March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced ...
Hosted on MSN

AstraZeneca’s IMFINZI® Granted Priority Review for Early-Stage Gastric Cancer Treatment

WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in ...
FierceBiotech

AstraZeneca flunks phase 3 lung cancer test in further setback to synthetic lethal mechanism

A phase 3 study of AstraZeneca’s ceralasertib has missed its primary endpoint, dealing another blow to efforts to use a synthetic lethal mechanism to overcome resistance to immuno-oncology drugs. The ...

EU Approves AstraZeneca's Imfinzi Combo as First Perioperative Treatment for Early Gastric Cancer

Imfinzi, or durvalumab, became the first and only perioperative immunotherapy authorized in the European Union for early-stage gastric and gastroesophageal cancers. The drugmaker said Monday the ...